Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Androgen deprivation therapy sensitizes triple negative breast cancer cells to immune-mediated lysis through androgen receptor independent modulation of osteoprotegerin.

Kwilas AR, Ardiani A, Gameiro SR, Richards J, Hall AB, Hodge JW.

Oncotarget. 2016 Apr 26;7(17):23498-511. doi: 10.18632/oncotarget.8274.

2.
3.
4.
5.

Radiation-induced survival responses promote immunogenic modulation to enhance immunotherapy in combinatorial regimens.

Gameiro SR, Ardiani A, Kwilas A, Hodge JW.

Oncoimmunology. 2014 Apr 29;3:e28643. eCollection 2014.

6.

Vaccine-mediated immunotherapy directed against a transcription factor driving the metastatic process.

Ardiani A, Gameiro SR, Palena C, Hamilton DH, Kwilas A, King TH, Schlom J, Hodge JW.

Cancer Res. 2014 Apr 1;74(7):1945-57. doi: 10.1158/0008-5472.CAN-13-2045. Epub 2014 Feb 11.

7.

Attacking malignant cells that survive therapy: Exploiting immunogenic modulation.

Hodge JW, Kwilas A, Ardiani A, Gameiro SR.

Oncoimmunology. 2013 Dec 1;2(12):e26937. Epub 2013 Nov 6.

8.

Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine.

Hamilton DH, Litzinger MT, Jales A, Huang B, Fernando RI, Hodge JW, Ardiani A, Apelian D, Schlom J, Palena C.

Oncotarget. 2013 Oct;4(10):1777-90.

9.

Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model.

Ardiani A, Farsaci B, Rogers CJ, Protter A, Guo Z, King TH, Apelian D, Hodge JW.

Clin Cancer Res. 2013 Nov 15;19(22):6205-18. doi: 10.1158/1078-0432.CCR-13-1026. Epub 2013 Sep 18.

10.

The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors.

Hodge JW, Ardiani A, Farsaci B, Kwilas AR, Gameiro SR.

Semin Oncol. 2012 Jun;39(3):323-39. doi: 10.1053/j.seminoncol.2012.02.006. Review.

11.

Enzymes to die for: exploiting nucleotide metabolizing enzymes for cancer gene therapy.

Ardiani A, Johnson AJ, Ruan H, Sanchez-Bonilla M, Serve K, Black ME.

Curr Gene Ther. 2012 Apr 1;12(2):77-91. Review.

12.

Comparative analysis of enzyme and pathway engineering strategies for 5FC-mediated suicide gene therapy applications.

Johnson AJ, Ardiani A, Sanchez-Bonilla M, Black ME.

Cancer Gene Ther. 2011 Aug;18(8):533-42. doi: 10.1038/cgt.2011.6. Epub 2011 Mar 11.

13.

Vaccines based on whole recombinant Saccharomyces cerevisiae cells.

Ardiani A, Higgins JP, Hodge JW.

FEMS Yeast Res. 2010 Dec;10(8):1060-9. doi: 10.1111/j.1567-1364.2010.00665.x. Review.

14.

Fusion enzymes containing HSV-1 thymidine kinase mutants and guanylate kinase enhance prodrug sensitivity in vitro and in vivo.

Ardiani A, Sanchez-Bonilla M, Black ME.

Cancer Gene Ther. 2010 Feb;17(2):86-96. doi: 10.1038/cgt.2009.60. Epub 2009 Sep 18.

15.

Bacterial cytosine deaminase mutants created by molecular engineering show improved 5-fluorocytosine-mediated cell killing in vitro and in vivo.

Fuchita M, Ardiani A, Zhao L, Serve K, Stoddard BL, Black ME.

Cancer Res. 2009 Jun 1;69(11):4791-9. doi: 10.1158/0008-5472.CAN-09-0615.

16.

Mutations at serine 37 in mouse guanylate kinase confer resistance to 6-thioguanine.

Ardiani A, Goyke A, Black ME.

Protein Eng Des Sel. 2009 Apr;22(4):225-32. doi: 10.1093/protein/gzn078. Epub 2009 Jan 10.

17.

Yeast cytosine deaminase mutants with increased thermostability impart sensitivity to 5-fluorocytosine.

Stolworthy TS, Korkegian AM, Willmon CL, Ardiani A, Cundiff J, Stoddard BL, Black ME.

J Mol Biol. 2008 Mar 28;377(3):854-69. doi: 10.1016/j.jmb.2008.01.002. Epub 2008 Jan 11.

Supplemental Content

Loading ...
Support Center